We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Prime Medicine Inc (PRME) USD0.00001

Sell:$5.22 Buy:$5.57 Change: $0.27 (4.76%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.27 (4.76%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: $0.27 (4.76%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.

Contact details

60 First St.
United States
+1 (617) 4650013

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$754.99 million
Shares in issue:
120.03 million
United States
US dollar

Key personnel

  • Keith Gottesdiener
    President, Chief Executive Officer, Director
  • Andrew Anzalone
    Co-Founder, Head of Prime Editing Platform
  • Allan Reine
    Chief Financial Officer
  • Meredith Goldwasser
    Senior Vice President - Strategy and Corporate Operations
  • Ann Lee
    Chief Technical Officer
  • Jeremy Duffield
    Chief Scientific Officer
  • Richard Brudnick
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.